SC
SYRS

Shay Capital’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Shay Capital’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-23,776
Closed -$93.9K – 441
2023
Q3 		$93.9K Sell
23,776
-2,650
-10% -$9.91K 0.01% 296
2023
Q2 		$83.2K Buy
26,426
+12,317
+87% +$39.6K 0.01% 346
2023
Q1 		$37.7K Buy
+14,109
New +$54.7K 0.01% 386

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Shay Capital's SYRS Position: Q4 2023 in Review

Shay Capital sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2023, closing a stake of 23,776 shares — an estimated $93.9K sold.

Shay Capital first reported a position in SYRS in Q1 2023 and held it in 3 quarters. The position peaked at $93.9K in Q3 2023. 58 funds tracked by Wall St. Rank hold SYRS as of Q4 2023.

  • Shay Capital reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Shay Capital sold 23,776 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $93.9K.
  • Shay Capital first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 3 quarters.
  • Shay Capital's Syros Pharmaceuticals, Inc. Common Stock position peaked at $93.9K in Q3 2023.
  • 58 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Shay Capital's 13F filing for Q4 2023, filed 14 Feb 2024.